» Articles » PMID: 31293377

Alzheimer Disease Pathogenesis: Insights From Molecular and Cellular Biology Studies of Oligomeric Aβ and Tau Species

Overview
Journal Front Neurosci
Date 2019 Jul 12
PMID 31293377
Citations 119
Authors
Affiliations
Soon will be listed here.
Abstract

Alzheimer disease (AD) represents an oncoming epidemic that without an effective treatment promises to exact extraordinary human and financial burdens. Studies of pathogenesis are essential for defining targets for discovering disease-modifying treatments. Past studies of AD neuropathology provided valuable, albeit limited, insights. Nevertheless, building on these findings, recent studies have provided an increasingly rich harvest of genetic, molecular and cellular data that are creating unprecedented opportunities to both understand and treat AD. Among the most significant are those documenting the presence within the AD brain of toxic oligomeric species of Aβ and tau. Existing data support the view that such species can propagate and spread within neural circuits. To place these findings in context we first review the genetics and neuropathology of AD, including AD in Down syndrome (AD-DS). We detail studies that support the existence of toxic oligomeric species while noting the significant unanswered questions concerning their precise structures, the means by which they spread and undergo amplification and how they induce neuronal dysfunction and degeneration. We conclude by offering a speculative synthesis for how oligomers of Aβ and tau initiate and drive pathogenesis. While 100 years after Alzheimer's first report there is much still to learn about pathogenesis and the discovery of disease-modifying treatments, the application of new concepts and sophisticated new tools are poised to deliver important advances for combatting AD.

Citing Articles

Comparative the efficacy and safety of Gosuranemab, Semorinemab, Tilavonemab, and Zagotenemab in patients with Alzheimer's disease: a systematic review and network meta-analysis of randomized controlled trials.

Cai W, Zhang H, Wu Y, Yao Y, Zhang J Front Aging Neurosci. 2025; 16:1465871.

PMID: 39945003 PMC: 11814219. DOI: 10.3389/fnagi.2024.1465871.


The Search for a Universal Treatment for Defined and Mixed Pathology Neurodegenerative Diseases.

ODay D Int J Mol Sci. 2025; 25(24.

PMID: 39769187 PMC: 11678063. DOI: 10.3390/ijms252413424.


Designed Cell-Penetrating Peptide Constructs for Inhibition of Pathogenic Protein Self-Assembly.

Kalmouni M, Oh Y, Alata W, Magzoub M Pharmaceutics. 2024; 16(11).

PMID: 39598566 PMC: 11597747. DOI: 10.3390/pharmaceutics16111443.


Multi-Protective Effects of Petunidin-3-O-(-coumaroylrutinoside)-5-O-glucoside on D-Gal-Induced Aging Mice.

Wang R, Ren L, Wang Y, Hu N, Tie F, Dong Q Int J Mol Sci. 2024; 25(20).

PMID: 39456797 PMC: 11506951. DOI: 10.3390/ijms252011014.


Validation of a functional human AD model with four AD therapeutics utilizing patterned ipsc-derived cortical neurons integrated with microelectrode arrays.

Caneus J, Autar K, Akanda N, Grillo M, Long C, Jackson M Sci Rep. 2024; 14(1):24875.

PMID: 39438515 PMC: 11496884. DOI: 10.1038/s41598-024-73869-9.


References
1.
Shinohara M, Petersen R, Dickson D, Bu G . Brain regional correlation of amyloid-β with synapses and apolipoprotein E in non-demented individuals: potential mechanisms underlying regional vulnerability to amyloid-β accumulation. Acta Neuropathol. 2013; 125(4):535-47. PMC: 3612369. DOI: 10.1007/s00401-013-1086-9. View

2.
Wiseman F, Al-Janabi T, Hardy J, Karmiloff-Smith A, Nizetic D, Tybulewicz V . A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome. Nat Rev Neurosci. 2015; 16(9):564-74. PMC: 4678594. DOI: 10.1038/nrn3983. View

3.
Cataldo A, Peterhoff C, Troncoso J, Gomez-Isla T, Hyman B, Nixon R . Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations. Am J Pathol. 2000; 157(1):277-86. PMC: 1850219. DOI: 10.1016/s0002-9440(10)64538-5. View

4.
Kvartsberg H, Duits F, Ingelsson M, Andreasen N, Ohrfelt A, Andersson K . Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease. Alzheimers Dement. 2014; 11(10):1180-90. DOI: 10.1016/j.jalz.2014.10.009. View

5.
Mulder S, Nielsen H, Blankenstein M, Eikelenboom P, Veerhuis R . Apolipoproteins E and J interfere with amyloid-beta uptake by primary human astrocytes and microglia in vitro. Glia. 2014; 62(4):493-503. DOI: 10.1002/glia.22619. View